Bristol Myers expanding direct-to-patient program with Eliquis and Sotyktu

Bristol Myers (BMY) announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with discounted prices for Eliquis – apixaban – and Sotyktu – deucravacitinib -. Eligible cash-pay patients can now purchase these medicines directly from BMS and lower their out-of-pocket costs. Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of the Bristol Myers Squibb-Pfizer Alliance program for Eliquis earlier this month. The platform will offer Sotyktu at more than 80% less than the current list price. Eligible cash-pay U.S. patients with a Sotyktu prescription will be able to purchase the medicine via BMS Patient Connect with access to shipping across all 50 states and Puerto Rico. BMS Patient Connect will also provide patient support resources and allow for the addition of other BMS medicines that are appropriate for this model in the future. Sotyktu is an oral prescription medication that is used to treat moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy – pills or injections that work inside the body – or phototherapy – treatment using specialized ultraviolet or UV light -.